Adicet Bio (ACET)
(Real Time Quote from BATS)
$1.34 USD
-0.05 (-3.60%)
Updated Sep 25, 2024 12:36 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Adicet Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 25 | 10 | 18 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 25 | 10 | 18 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 152 | 98 | 71 | 57 | 85 |
Income After Depreciation & Amortization | -152 | -73 | -61 | -39 | -85 |
Non-Operating Income | 9 | 3 | -1 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -143 | -70 | -62 | -39 | -83 |
Income Taxes | 0 | 0 | 0 | -3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -143 | -70 | -62 | -37 | -83 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -143 | -70 | -62 | -37 | -83 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -126 | -70 | -60 | -38 | -85 |
Depreciation & Amortization (Cash Flow) | 26 | 3 | 2 | 1 | 0 |
Income After Depreciation & Amortization | -152 | -73 | -61 | -39 | -85 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.04 | 41.08 | 30.95 | 7.32 | 4.90 |
Diluted EPS Before Non-Recurring Items | -2.86 | -1.70 | -2.00 | -5.01 | -16.87 |
Diluted Net EPS (GAAP) | -3.31 | -1.70 | -2.00 | -5.01 | -16.86 |
Fiscal Year end for Adicet Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 32.85 | 30.87 | 31.57 | 52.26 | 34.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | -32.85 | -30.87 | -31.57 | -52.26 | -34.89 |
Non-Operating Income | 2.95 | 2.86 | 2.08 | 2.38 | 2.49 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -29.90 | -28.02 | -29.49 | -49.89 | -32.40 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -29.90 | -28.02 | -29.49 | -49.89 | -32.40 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -29.90 | -28.02 | -29.49 | -49.89 | -32.40 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 90.63 | 79.07 | 43.04 | 42.98 | 42.96 |
Diluted EPS Before Non-Recurring Items | -0.33 | -0.35 | -0.69 | -0.71 | -0.75 |
Diluted Net EPS (GAAP) | -0.33 | -0.35 | -0.68 | -1.16 | -0.75 |